Literature DB >> 34651095

Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an NTRK2 Fusion: The Impact of Integrated Genomic Profiling.

Ross Mangum1, Jacquelyn Reuther2, Kelsey C Bertrand1, Raghu Chandramohan3, Marcia K Kukreja4, Arnold C Paulino5, Donna Muzny3,6, Jianhong Hu3,6, Richard A Gibbs3,6, Daniel J Curry7, Fatema Malbari1,8, Murali M Chintagumpala1,9, Adekunle M Adesina2,9,10, Kevin E Fisher2,9,10, Stephen C Mack1,9, Sharon E Plon1,3,6,9, Angshumoy Roy1,2,9,10, D Williams Parsons1,3,6,9, Frank Y Lin1,9.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34651095      PMCID: PMC8509924          DOI: 10.1200/PO.20.00375

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


× No keyword cloud information.
  18 in total

1.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.

Authors:  Kristian W Pajtler; Hendrik Witt; Martin Sill; David T W Jones; Volker Hovestadt; Fabian Kratochwil; Khalida Wani; Ruth Tatevossian; Chandanamali Punchihewa; Pascal Johann; Jüri Reimand; Hans-Jörg Warnatz; Marina Ryzhova; Steve Mack; Vijay Ramaswamy; David Capper; Leonille Schweizer; Laura Sieber; Andrea Wittmann; Zhiqin Huang; Peter van Sluis; Richard Volckmann; Jan Koster; Rogier Versteeg; Daniel Fults; Helen Toledano; Smadar Avigad; Lindsey M Hoffman; Andrew M Donson; Nicholas Foreman; Ekkehard Hewer; Karel Zitterbart; Mark Gilbert; Terri S Armstrong; Nalin Gupta; Jeffrey C Allen; Matthias A Karajannis; David Zagzag; Martin Hasselblatt; Andreas E Kulozik; Olaf Witt; V Peter Collins; Katja von Hoff; Stefan Rutkowski; Torsten Pietsch; Gary Bader; Marie-Laure Yaspo; Andreas von Deimling; Peter Lichter; Michael D Taylor; Richard Gilbertson; David W Ellison; Kenneth Aldape; Andrey Korshunov; Marcel Kool; Stefan M Pfister
Journal:  Cancer Cell       Date:  2015-05-11       Impact factor: 31.743

Review 2.  TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Authors:  Shivaani Kummar; Ulrik N Lassen
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

3.  NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.

Authors:  James P Solomon; Irina Linkov; Andrea Rosado; Kerry Mullaney; Ezra Y Rosen; Denise Frosina; Achim A Jungbluth; Ahmet Zehir; Ryma Benayed; Alexander Drilon; David M Hyman; Marc Ladanyi; Anthony N Sireci; Jaclyn F Hechtman
Journal:  Mod Pathol       Date:  2019-08-02       Impact factor: 7.842

Review 4.  Larotrectinib for the treatment of TRK fusion solid tumors.

Authors:  Theodore W Laetsch; Douglas S Hawkins
Journal:  Expert Rev Anticancer Ther       Date:  2018-10-24       Impact factor: 4.512

5.  Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.

Authors:  Theodore W Laetsch; Steven G DuBois; Leo Mascarenhas; Brian Turpin; Noah Federman; Catherine M Albert; Ramamoorthy Nagasubramanian; Jessica L Davis; Erin Rudzinski; Angela M Feraco; Brian B Tuch; Kevin T Ebata; Mark Reynolds; Steven Smith; Scott Cruickshank; Michael C Cox; Alberto S Pappo; Douglas S Hawkins
Journal:  Lancet Oncol       Date:  2018-03-29       Impact factor: 41.316

Review 6.  Pediatric Ependymoma.

Authors:  Nicholas A Vitanza; Sonia Partap
Journal:  J Child Neurol       Date:  2015-10-26       Impact factor: 1.987

7.  TPM3-NTRK1 fusion in a pleomorphic xanthoastrocytoma presenting with haemorrhage in a child.

Authors:  Katherine Clark Pehlivan; Denise M Malicki; Michael L Levy; John Ross Crawford
Journal:  BMJ Case Rep       Date:  2020-03-12

8.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors.

Authors:  D Williams Parsons; Angshumoy Roy; Yaping Yang; Tao Wang; Sarah Scollon; Katie Bergstrom; Robin A Kerstein; Stephanie Gutierrez; Andrea K Petersen; Abhishek Bavle; Frank Y Lin; Dolores H López-Terrada; Federico A Monzon; M John Hicks; Karen W Eldin; Norma M Quintanilla; Adekunle M Adesina; Carrie A Mohila; William Whitehead; Andrew Jea; Sanjeev A Vasudevan; Jed G Nuchtern; Uma Ramamurthy; Amy L McGuire; Susan G Hilsenbeck; Jeffrey G Reid; Donna M Muzny; David A Wheeler; Stacey L Berg; Murali M Chintagumpala; Christine M Eng; Richard A Gibbs; Sharon E Plon
Journal:  JAMA Oncol       Date:  2016-05-01       Impact factor: 31.777

9.  Molecular and clinicopathologic features of gliomas harboring NTRK fusions.

Authors:  Matthew Torre; Varshini Vasudevaraja; Jonathan Serrano; Michael DeLorenzo; Seth Malinowski; Anne-Florence Blandin; Melanie Pages; Azra H Ligon; Fei Dong; David M Meredith; MacLean P Nasrallah; Craig Horbinski; Sonika Dahiya; Keith L Ligon; Mariarita Santi; Shakti H Ramkissoon; Mariella G Filbin; Matija Snuderl; Sanda Alexandrescu
Journal:  Acta Neuropathol Commun       Date:  2020-07-14       Impact factor: 7.578

10.  Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.

Authors:  David S Ziegler; Marie Wong; Chelsea Mayoh; Amit Kumar; Maria Tsoli; Emily Mould; Vanessa Tyrrell; Dong-Anh Khuong-Quang; Mark Pinese; Velimir Gayevskiy; Richard J Cohn; Loretta M S Lau; Mark Reynolds; Michael C Cox; Andrew Gifford; Michael Rodriguez; Mark J Cowley; Paul G Ekert; Glenn M Marshall; Michelle Haber
Journal:  Br J Cancer       Date:  2018-09-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.